Researcher
Sébastien Anguille
- Research Expertise:Cancer; hematological malignancies; acute myeloid leukemia; immunotherapy; dendritic cells; gene-modified T cells including chimeric antigen receptor (CAR) T cell; translational research; clinical studies
- Keywords:T CYTOTOXIC LYMPHOCYTE, DENDRITIC CELLS, CLINICAL TRIAL, CANCER VACCINES, CANCER IMMUNOTHERAPY, ELECTROPORATION, Medicine
- Disciplines:Hematology, Cancer therapy
- Research techniques:Cell culture; multiparameter flow cytometry; ELISA and ELISpot; cytotoxicity experiments; mRNA electroporation; GMP production of dendritic cell vaccines and CAR-T cells
- Users of research expertise:Academia; biotech companies; pharmaceutical companies
Affiliations
- Laboratory for Experimental Hematology (LEH) (Research group)
Responsible
From1 Oct 2020 → Today - Laboratory for Experimental Hematology (LEH) (Research group)
Member
From1 Jan 2019 → 30 Sep 2020 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2018 → 31 Dec 2018 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2008 → 31 Jul 2013
Projects
1 - 10 of 16
- Development of a novel chimeric antigen receptor (CAR)-T cell therapy for acute myeloid leukemia.From1 Oct 2023 → TodayFunding: BOF - doctoral mandates
- BCMA immunoPET to predict and monitor treatment response to CAR-based cellular therapies in multiple myeloma.From1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Learning the design language of CAR structural components using a high-throughput screening method.From1 Sep 2022 → 28 Feb 2023Funding: Foreign Nonprofit organisations and equivalents
- Targeting the NF-κB pathway with targeted protein degradation for the treatment of hematological malignancies.From1 Sep 2022 → TodayFunding: Baekeland
- Flow Cytometry and Cell Sorting Core Facility Uantwerpen (FACSUA)From1 Jan 2022 → TodayFunding: BOF - research organisations
- MulTplex project: Innovating on combinatorial genetically engineered adoptive Tcell therapies against hematological diseases.From1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- Preclinical development of novel chimeric antigen receptor (CAR)-modified cell-based immunotherapy approaches for hematological malignancies.From1 Oct 2021 → TodayFunding: BOF - doctoral mandates
- Post-transplant infusion of CD19 CAR-armored donor lymphocytes in adult patients with B-cell hematological malignancies: a phase I/IIa study.From1 Oct 2021 → TodayFunding: Nonprofit institution or equivalents
- ANCHOR project - Antigenspecific non signaling CARs as hemato-oncological remedy.From22 Jun 2021 → 22 Jun 2022Funding: Foundations, funds and other with scientific goal
- Identification and validation of T cell receptor (TCR) pairs for TCR-T cell therapy for AML and NHL (HEME TCR).From1 Jun 2021 → TodayFunding: VLAIO - research project companies
Publications
31 - 40 of 81
- CD56 homodimerization and participation in anti-tumor immune effector cell functioning(2019)
Authors: Heleen Van Acker, Zoë Van Acker, Maarten Versteven, Peter Ponsaerts, Daniela Pende, Zwi Berneman, Sébastien Anguille, Vigor Van Tendeloo, Evelien Smits
- Interleukin-15-cultered dendritic cells enhance anti-tumor gamme delta T cell functions through IL-15 secretion(2018)
Authors: Heleen Van Acker, Sébastien Anguille, Hans De Reu, Evelien Smits, Vigor Van Tendeloo
- Paroxysmal nocturnal haemoglobinuria(2017)
Authors: K. Saevels, Sébastien Anguille
Pages: 259 - 264 - Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells(2017)
Authors: Heleen Van Acker, Ottavio Beretta, Sébastien Anguille, Lien De Caluwe, Angela Papagna, Johan Van den Bergh, Yannick Willemen, Herman Goossens, Zwi Berneman, Vigor Van Tendeloo, et al.
Pages: 13652 - 13665 - Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia(2017)
Authors: Sébastien Anguille, Ann Van de Velde, Evelien Smits, Vigor Van Tendeloo, Gunnar Juliusson, Nathalie Cools, Barbara Stein, Eva Lion, Ann van Driessche, Irma Vandenbosch, et al.
Pages: 1713 - 1721 - Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells(2016)
Authors: Heleen Van Acker, Sébastien Anguille, Yannick Willemen, Johan Van den Bergh, Eva Lion, Evelien Smits, Vigor Van Tendeloo
- Generation and cryopreservation of clinical grade Wilms' tumor 1 mRNA-loaded dendritic cell vaccines for cancer immunotherapy(2016)
Authors: Evelien Smits, Barbara Stein, Eva Lion, Vigor Van Tendeloo, Yannick Willemen, Sébastien Anguille
Pages: 27 - 35 - The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells(2016)
Authors: Yannick Willemen, Johan Van den Bergh, Sarah M. Bonte, Sébastien Anguille, Carlo Heirman, Barbara Stein, Tessa Kerre, Kris Thielemans, Marc Peeters, Vigor Van Tendeloo, et al.
Pages: 73960 - 73970 - Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium(2016)
Authors: Ann Van de Velde, Philippe Beutels, Evelien Smits, Vigor Van Tendeloo, Sébastien Anguille, A. Verlinden, Alain Gadisseur, Wilfried Schroyens, S. Dom, I. Cornille
Pages: 26 - 29 - Bisphosphonates for cancer treatment(2016)
Authors: Heleen Van Acker, Sébastien Anguille, Yannick Willemen, Evelien Smits, Vigor Van Tendeloo
Pages: 24 - 40